Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | PI103 | 3 | 72 | 0.01 | 3371.5 | 3295.0 | 1180.5 | -2.0 | 1.030 | 1.020 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PI103 | 3 | 72 | 0.032 | 3206.0 | 3295.0 | 1180.5 | -1.49 | 0.963 | 0.973 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PI103 | 3 | 72 | 0.1 | 3147.3 | 3295.0 | 1180.5 | -1.0 | 0.939 | 0.955 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PI103 | 3 | 72 | 0.32 | 2953.3 | 3295.0 | 1180.5 | -0.495 | 0.857 | 0.896 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PI103 | 3 | 72 | 1.0 | 2311.5 | 3295.0 | 1180.5 | 0.0 | 0.574 | 0.702 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PI103 | 3 | 72 | 3.2 | 1384.8 | 3295.0 | 1180.5 | 0.505 | 0.114 | 0.420 | 1.481 | HCC38 PI103 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.001 | 3163.5 | 3077.8 | 1180.5 | -3.0 | 1.040 | 1.030 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.0032 | 3085.5 | 3077.8 | 1180.5 | -2.49 | 1.000 | 1.000 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.01 | 2884.0 | 3077.8 | 1180.5 | -2.0 | 0.908 | 0.937 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.032 | 3023.8 | 3077.8 | 1180.5 | -1.49 | 0.975 | 0.982 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.1 | 3135.5 | 3077.8 | 1180.5 | -1.0 | 1.030 | 1.020 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 0.32 | 3011.8 | 3077.8 | 1180.5 | -0.495 | 0.969 | 0.979 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 1.0 | 2809.8 | 3077.8 | 1180.5 | 0.0 | 0.872 | 0.913 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | PIK-93 | 3 | 72 | 3.2 | 2257.8 | 3077.8 | 1180.5 | 0.505 | 0.598 | 0.734 | 1.382 | HCC38 PIK93 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.001 | 2383.0 | 3158.8 | 1180.5 | -3.0 | 0.640 | 0.754 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.0032 | 2352.3 | 3158.8 | 1180.5 | -2.49 | 0.625 | 0.745 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.01 | 2353.5 | 3158.8 | 1180.5 | -2.0 | 0.626 | 0.745 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.032 | 2332.3 | 3158.8 | 1180.5 | -1.49 | 0.615 | 0.738 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.1 | 2306.5 | 3158.8 | 1180.5 | -1.0 | 0.603 | 0.730 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 0.32 | 2256.0 | 3158.8 | 1180.5 | -0.495 | 0.578 | 0.714 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 1.0 | 2194.3 | 3158.8 | 1180.5 | 0.0 | 0.547 | 0.695 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | Sirolimus | 3 | 72 | 3.2 | 2169.5 | 3158.8 | 1180.5 | 0.505 | 0.535 | 0.687 | 1.420 | HCC38 Rapamycin 0 3 72 |
| HCC38 | TGX221 | 3 | 72 | 0.001 | 3169.8 | 3303.0 | 1180.5 | -3.0 | 0.945 | 0.960 | 1.484 | HCC38 TGX221 0 3 72 |
| HCC38 | TGX221 | 3 | 72 | 0.0032 | 3258.8 | 3303.0 | 1180.5 | -2.49 | 0.982 | 0.987 | 1.484 | HCC38 TGX221 0 3 72 |
| HCC38 | TGX221 | 3 | 72 | 0.01 | 3167.5 | 3303.0 | 1180.5 | -2.0 | 0.944 | 0.959 | 1.484 | HCC38 TGX221 0 3 72 |